Malta - anglès - Medicines Authority

teva pharma b.v. (mijdrecht) industrieweg 23, p.o. box 217, 3640 ae mijdrecht, netherlands - cabergoline - tablet - cabergoline 0.5 mg - other gynecologicals

Malta - anglès - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - tablet - cabergoline 0.5 mg - other gynecologicals

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

multichem nz limited - pergolide mesilate 1.31mg equivalent to 1 mg pergolide - tablet - 1 mg - active: pergolide mesilate 1.31mg equivalent to 1 mg pergolide excipient: iron oxide red magnesium stearate mannitol microcrystalline cellulose starch titanium dioxide - pergolide mesylate is indicated as second line therapy in patients who are intolerant or fail treatment with a non-ergot compound, as adjunctive treatment with levodopa in combination with decarboxylase inhibitors in the treatment of parkinson's disease. treatment should be initiated under specialist supervision. the benefit of continued treatment should be regularly reassessed taking into account the risk of fibrotic reactions and valvulopathy.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - cabergoline 0.5mg - tablet - 0.5 mg - active: cabergoline 0.5mg excipient: lactose leucine - prevention of the onset of lactation in the puerperium only for clearly defined medical reasons: arrow - cabergoline is indicated for the inhibition of physiological lactation soon after delivery. 1. after parturition, when breast feeding is contraindicated due to medical reasons related to the mother or the new-born. 2. after stillbirth or abortion. treatment of hyperprolactinaemic disorders: cabergoline is indicated for the treatment of dysfunctions associated with hyperprolactinaemia, including amenorrhoea, oligomenorrhoea, anovulation and galactorrhoea. cabergoline is indicated in patients with prolactin-secreting pituitary adenomas (micro- and macroprolactinomas), idiopathic hyperprolactinaemia, or empty sella syndrome with associated hyperprolactinaemia, which represent the basic underlying pathologies contributing to the above clinical manifestations.

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

arrow generics limited - cabergoline - tablets - 0.5 milligram

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - cabergoline, quantity: 500 microgram - tablet - excipient ingredients: lactose; magnesium stearate - ? inhibition of physiological lactation ,cabergoline is indicated for the prevention of the onset of physiological lactation in the puerperium for clearly defined medical reasons. ,? treatment of hyperprolactinaemic disorders ,cabergoline is indicated for the treatment of pathological hyperprolactinaemia.

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

renata pharmaceuticals (ireland) limited - cabergoline - tablet - cabergoline

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

renata pharmaceuticals (ireland) limited - cabergoline - tablet - cabergoline

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - pergolide mesilate - oral tablet - 1mg

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - pergolide mesilate - oral tablet - 1mg